{"id":745410,"date":"2016-03-07T08:00:00","date_gmt":"2016-03-07T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/"},"modified":"2025-11-07T01:25:57","modified_gmt":"2025-11-07T06:25:57","slug":"fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/","title":{"rendered":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Application Based on Data from KEYNOTE-010, Which Showed Superior        Overall Survival for Patients Taking KEYTRUDA Compared to Chemotherapy        in Patients with PD-L1 Expression on One Percent or More of the Cancer        Cells     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for review a new supplemental Biologics License Application<br \/>\n      (sBLA) for KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      therapy, to include data from KEYNOTE-010. The trial was a pivotal Phase<br \/>\n      2\/3 study designed to evaluate KEYTRUDA compared to chemotherapy based<br \/>\n      on prospective measurement of PD-L1 expression in previously treated<br \/>\n      patients with advanced non-small cell lung cancer. KEYNOTE-010 was<br \/>\n      published in <i>The Lancet <\/i>in December 2015.\n    <\/p>\n<p>\n      \u201cThe data from KEYNOTE-010 demonstrated an overall survival benefit in<br \/>\n      patients with PD-L1 expression on one percent or more of the cancer<br \/>\n      cells,\u201d said Roger Dansey, M.D., senior vice president and therapeutic<br \/>\n      area head, oncology late-stage development, Merck Research Laboratories.<br \/>\n      \u201cWe look forward to working with the FDA over the course of the<br \/>\n      application review process and remain committed to advancing our broad<br \/>\n      clinical program for cancers where patients are in need of new options,<br \/>\n      including lung cancer.\u201d\n    <\/p>\n<p>\n      KEYTRUDA is currently indicated in the U.S. for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 as determined<br \/>\n      by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA<br \/>\n      (pembrolizumab). The NSCLC indication, approved under accelerated<br \/>\n      approval, was based on tumor response rate and durability of response in<br \/>\n      patients with PD-L1 expression on 50 percent or more of the cancer<br \/>\n      cells. Under accelerated approval, improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In accordance with the accelerated approval process, the data from<br \/>\n      KEYNOTE-010 was intended to serve as the confirmatory trial for<br \/>\n      receiving full approval, establishing the clinical benefit by<br \/>\n      demonstrating improved survival over standard chemotherapy. Findings<br \/>\n      from this study were presented at the European Society for Medical<br \/>\n      Oncology (ESMO) Asia 2015 Congress and published in <i>The Lancet <\/i>(see<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fprescription-medicine-news%2Fmercks-keytruda-pembrolizumab-significantly-improves-surviva&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=news+release&amp;index=1&amp;md5=faf985983703b48c5a58d0c627b10560\" rel=\"nofollow\">news<br \/>\n      release<\/a>).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the U.S. for the treatment of patients with<br \/>\n      unresectable or metastatic melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. The NSCLC<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is administered at a dose of 2 mg\/kg as an intravenous infusion<br \/>\n      over 30 minutes every three weeks for the approved indications.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis occurred in 19 (3.5%) of 550 patients,<br \/>\n      including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis.<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients, including<br \/>\n      Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as clinically indicated.<br \/>\n      Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3 or 4<br \/>\n      hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%) hyperthyroidism. Hypothyroidism occurred in 38 (6.9%)<br \/>\n      of 550 patients, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2,117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA (pembrolizumab) and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the immune-mediated adverse<br \/>\n      reaction remains at Grade 1 or less following corticosteroid taper.<br \/>\n      Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse<br \/>\n      reaction that recurs and for any life-threatening immune-mediated<br \/>\n      adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2,117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients. Serious adverse reactions occurred in 38% of patients. The<br \/>\n      most frequent serious adverse reactions reported in at least 2% of<br \/>\n      patients were pleural effusion, pneumonia, dyspnea, pulmonary embolism,<br \/>\n      and pneumonitis. The most common adverse reactions (reported in at least<br \/>\n      20% of patients) were fatigue (44%), cough (29%), decreased appetite<br \/>\n      (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA (pembrolizumab) have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=c3899450f2d5b89ceedf5b11b92c1511\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=5c86c634d8283b76585136bc5dc2a5ac\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=c3c60894ef8259508b382c16224d2e96\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=ecb7b581c0cc84b1c21e78ca4578fffc\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=6266425eff6c3b7b7c9c8124ac0039a6\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=34e2d2f15b04e86d5f2e6a3242e3b19e\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful.&nbsp;If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=4fd740ae632965b24c5544a88315e734\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=33fd146f22e233efb426d062171b25ac\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a><br \/>\n      and the\n    <\/p>\n<p>\n      Medication Guide for KEYTRUDA at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51291730&amp;newsitemid=20160307005748&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=511a7cebb86b0408123b9a2496d99cdd\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160307005748r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, (267) 305-3558<br \/>or<br \/>Kim        Hamilton, (908) 740-1863<br \/>or<br \/>Investor:<br \/>Teri Loxam, (908)        740-1986<br \/>or<br \/>Justin Holko, (908) 740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, to include data from KEYNOTE-010. The trial was a pivotal Phase 2\/3 study designed to evaluate KEYTRUDA compared to chemotherapy based on prospective measurement of PD-L1 expression in previously treated patients with advanced non-small cell lung cancer. KEYNOTE-010 was published in The Lancet in December 2015. \u201cThe data from KEYNOTE-010 demonstrated an overall survival benefit in patients with PD-L1 expression on one percent or more of the cancer cells,\u201d said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cWe look forward to working with the FDA over the course of the application review process and remain committed to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-745410","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, to include data from KEYNOTE-010. The trial was a pivotal Phase 2\/3 study designed to evaluate KEYTRUDA compared to chemotherapy based on prospective measurement of PD-L1 expression in previously treated patients with advanced non-small cell lung cancer. KEYNOTE-010 was published in The Lancet in December 2015. \u201cThe data from KEYNOTE-010 demonstrated an overall survival benefit in patients with PD-L1 expression on one percent or more of the cancer cells,\u201d said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cWe look forward to working with the FDA over the course of the application review process and remain committed to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\\\/\",\"name\":\"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-03-07T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, to include data from KEYNOTE-010. The trial was a pivotal Phase 2\/3 study designed to evaluate KEYTRUDA compared to chemotherapy based on prospective measurement of PD-L1 expression in previously treated patients with advanced non-small cell lung cancer. KEYNOTE-010 was published in The Lancet in December 2015. \u201cThe data from KEYNOTE-010 demonstrated an overall survival benefit in patients with PD-L1 expression on one percent or more of the cancer cells,\u201d said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cWe look forward to working with the FDA over the course of the application review process and remain committed to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:57+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/","name":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-03-07T08:00:00+00:00","dateModified":"2025-11-07T06:25:57+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae (pembrolizumab) in Advanced Non-Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5ad7c73c-1af3-4e44-bc6a-1a38a50bbd8e","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Accepts-Supplemental-Biologics-License-Application-sBLA-for-KEYTRUDA-pembrolizumab-in-Advanced-Non-Small-Cell-Lung-Cancer-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745410\/revisions"}],"predecessor-version":[{"id":3674801,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745410\/revisions\/3674801"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745410"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}